Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers

This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvas...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and pharmacokinetics Vol. 34; no. 1; pp. 78 - 86
Main Authors Mori, Daiki, Kashihara, Yushi, Yoshikado, Takashi, Kimura, Miyuki, Hirota, Takeshi, Matsuki, Shunji, Maeda, Kazuya, Irie, Shin, Ieiri, Ichiro, Sugiyama, Yuichi, Kusuhara, Hiroyuki
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities. [Display omitted]
AbstractList This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities.
This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities. [Display omitted]
This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities.This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities.
Author Hirota, Takeshi
Sugiyama, Yuichi
Mori, Daiki
Yoshikado, Takashi
Maeda, Kazuya
Kashihara, Yushi
Ieiri, Ichiro
Irie, Shin
Matsuki, Shunji
Kimura, Miyuki
Kusuhara, Hiroyuki
Author_xml – sequence: 1
  givenname: Daiki
  surname: Mori
  fullname: Mori, Daiki
  organization: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
– sequence: 2
  givenname: Yushi
  surname: Kashihara
  fullname: Kashihara, Yushi
  organization: Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
– sequence: 3
  givenname: Takashi
  surname: Yoshikado
  fullname: Yoshikado, Takashi
  organization: Sugiyama Lab, RIKEN Innovation Center, RIKEN, Yokohama, Japan
– sequence: 4
  givenname: Miyuki
  surname: Kimura
  fullname: Kimura, Miyuki
  organization: Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, 813-0017, Japan
– sequence: 5
  givenname: Takeshi
  surname: Hirota
  fullname: Hirota, Takeshi
  organization: Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
– sequence: 6
  givenname: Shunji
  surname: Matsuki
  fullname: Matsuki, Shunji
  organization: Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, 813-0017, Japan
– sequence: 7
  givenname: Kazuya
  surname: Maeda
  fullname: Maeda, Kazuya
  organization: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
– sequence: 8
  givenname: Shin
  surname: Irie
  fullname: Irie, Shin
  organization: Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, 813-0017, Japan
– sequence: 9
  givenname: Ichiro
  surname: Ieiri
  fullname: Ieiri, Ichiro
  organization: Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
– sequence: 10
  givenname: Yuichi
  surname: Sugiyama
  fullname: Sugiyama, Yuichi
  organization: Sugiyama Lab, RIKEN Innovation Center, RIKEN, Yokohama, Japan
– sequence: 11
  givenname: Hiroyuki
  surname: Kusuhara
  fullname: Kusuhara, Hiroyuki
  email: kusuhara@mol.f.u-tokyo.ac.jp
  organization: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30528195$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1v1DAQhi1URNuFP8AB-ciBBE_sfElcSlUoUqVyKGfLsSddL4kdbKfS_gd-NMluy6GHnmYOz_NKM-85OXHeISHvgeXAoPq8y804_c4LBk3O2pwx_oqcQdOwjLUFO1l2LupM8Ko-Jecx7haAl6J4Q045K4sG2vKM_L3qe9SJ-p7eXtz9hK9A79H5tJ8wUu_oNKg4Kqq90-hSUMl6F1canfErOcf_Ypy7uCKLqZyhJsz38dNhTVu0gaoYvbaHCGod3aIa0nZPH_wwu4QY4lvyuldDxHePc0N-fbu6u7zObm6__7i8uMk0b1jKSmhAdLytQTGusVNClELVXS1Ux3vFmalq4GBqzVjXaxAGmRbQ67IU0DLgG_LxmDsF_2fGmORoo8ZhUA6Xg2QBZQlV1dTVgn54ROduRCOnYEcV9vLpgwvQHAEdfIwBe6ltOty4vMIOEphcy5I7uZYl17Ika-XaxYYUz9Sn9BelL0cJlwc9WAwyaotLO8aGpUhpvH1J_wcu8q5l
CitedBy_id crossref_primary_10_1016_j_ejps_2020_105264
crossref_primary_10_31146_1682_8658_ecg_206_10_70_76
crossref_primary_10_1002_cpt_2713
crossref_primary_10_1007_s43440_021_00319_y
crossref_primary_10_1111_bcp_15679
crossref_primary_10_1124_dmd_121_000521
crossref_primary_10_1080_17425255_2019_1681399
crossref_primary_10_3389_fphar_2021_802539
crossref_primary_10_3390_molecules26185500
crossref_primary_10_1016_j_xphs_2023_09_016
crossref_primary_10_1038_s41598_020_70140_9
crossref_primary_10_1124_dmd_119_089474
crossref_primary_10_1002_jcph_2119
crossref_primary_10_1124_pharmrev_121_000449
crossref_primary_10_1111_cts_13272
crossref_primary_10_1002_cpt_1998
crossref_primary_10_1002_psp4_70008
crossref_primary_10_1016_j_dmpk_2019_12_004
crossref_primary_10_1007_s12272_023_01476_9
crossref_primary_10_1002_psp4_12582
crossref_primary_10_1111_cts_12625
crossref_primary_10_1016_j_xphs_2021_02_011
crossref_primary_10_1002_cpt_2053
crossref_primary_10_1007_s00280_021_04314_1
crossref_primary_10_1002_cpt_2375
crossref_primary_10_3999_jscpt_51_205
crossref_primary_10_1016_j_jphs_2021_10_010
crossref_primary_10_1021_acsptsci_3c00116
crossref_primary_10_1124_dmd_123_001074
crossref_primary_10_3390_biom15030428
crossref_primary_10_1016_j_yamp_2022_05_003
crossref_primary_10_1016_j_xphs_2019_03_021
crossref_primary_10_1124_dmd_124_001708
crossref_primary_10_1021_acs_molpharmaceut_0c00903
crossref_primary_10_2217_pme_2022_0041
crossref_primary_10_1002_jcph_1817
crossref_primary_10_1016_j_apsb_2022_03_009
crossref_primary_10_1016_j_dmpk_2020_09_003
crossref_primary_10_3389_fphar_2021_713567
crossref_primary_10_1002_cpt_1695
crossref_primary_10_1124_dmd_123_001285
crossref_primary_10_1002_cpt_2905
crossref_primary_10_1002_cpt_2429
crossref_primary_10_1111_cts_13731
crossref_primary_10_1124_dmd_122_000972
crossref_primary_10_1111_bph_16205
crossref_primary_10_1111_cts_12888
crossref_primary_10_1111_cts_12889
crossref_primary_10_1080_00498254_2019_1629043
crossref_primary_10_1124_dmd_119_087924
crossref_primary_10_1016_j_dmd_2024_100028
crossref_primary_10_1007_s40262_021_01004_2
crossref_primary_10_1002_cpt_2672
Cites_doi 10.1097/FPC.0b013e3282fb02a3
10.1002/cpt.749
10.1002/jcph.723
10.1124/dmd.116.070276
10.1124/pr.113.007518
10.1248/bpb.b14-00767
10.1016/j.xphs.2017.03.010
10.1016/j.clpt.2006.06.010
10.1124/pr.110.002857
10.1016/j.jchromb.2017.12.008
10.1124/dmd.117.075531
10.1146/annurev-pharmtox-010611-134529
10.1111/bcp.13207
10.1097/FPC.0b013e3283517012
10.1007/s11095-018-2416-3
10.1007/s10038-008-0324-9
10.3109/00498254.2015.1085111
10.1007/s40262-018-0648-3
10.4155/bio-2017-0181
10.1007/s11095-017-2168-5
10.1016/j.xphs.2017.04.007
10.1517/17425250902976854
10.1016/j.cca.2006.05.010
10.1124/jpet.116.232066
10.1124/jpet.116.234914
10.1111/j.1349-7006.2008.00765.x
10.1124/pr.116.013326
10.1124/dmd.116.074740
10.1002/cpt.983
10.1002/psp4.12315
10.1002/cpt.434
10.1124/dmd.115.063347
10.1124/dmd.115.067694
10.1007/s11095-017-2184-5
10.1177/0091270007312153
10.1124/dmd.117.075275
ContentType Journal Article
Copyright 2018 The Japanese Society for the Study of Xenobiotics
Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2018 The Japanese Society for the Study of Xenobiotics
– notice: Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.dmpk.2018.09.003
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1880-0920
EndPage 86
ExternalDocumentID 30528195
10_1016_j_dmpk_2018_09_003
S1347436718300776
Genre Clinical Trial
Journal Article
GroupedDBID ---
--M
0R~
29G
2WC
4.4
457
53G
5GY
7-5
8P~
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AATCM
AAXUO
ABJNI
ABMAC
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
AEBSH
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BAWUL
BKOJK
BKOMP
BLXMC
CS3
DIK
DU5
E3Z
EBS
EFJIC
EFLBG
EJD
F5P
FDB
FEDTE
FIRID
FYGXN
GBLVA
GX1
HH5
HVGLF
HZ~
JMI
JSF
JSH
KOM
KQ8
M41
MOJWN
M~E
O9-
OAUVE
RJT
RNS
ROL
RZJ
SPCBC
SSP
SSZ
T5K
TKC
TR2
~G-
AAQFI
AATTM
AAXKI
AAYWO
AAYXX
ACVFH
ADCNI
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
BNPGV
CITATION
OVT
SSH
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c380t-51814b3971a03ceba4454a7b74ab3fa30d67131d7c00bfc14de0c41fc55419013
IEDL.DBID AIKHN
ISSN 1347-4367
1880-0920
IngestDate Fri Jul 11 07:22:29 EDT 2025
Thu Apr 03 07:03:03 EDT 2025
Thu Apr 24 22:51:52 EDT 2025
Tue Jul 01 03:08:28 EDT 2025
Fri Feb 23 02:27:11 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords GCDCA-S
Endogenous substrate
Biomarker
CDCA-24G
Coproporphyrin I
Gender difference
DDI
OATP1B3
MRM
Statin
LC–MS/MS
OATP1B1
AUC
CV
CP-I
OCT2
MATE1
TLCA-S
OATP1B1 genotype
LCA-S
GLCA-S
Language English
License Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c380t-51814b3971a03ceba4454a7b74ab3fa30d67131d7c00bfc14de0c41fc55419013
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 30528195
PQID 2155166876
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2155166876
pubmed_primary_30528195
crossref_citationtrail_10_1016_j_dmpk_2018_09_003
crossref_primary_10_1016_j_dmpk_2018_09_003
elsevier_sciencedirect_doi_10_1016_j_dmpk_2018_09_003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2019
2019-02-00
2019-Feb
20190201
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: February 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Drug metabolism and pharmacokinetics
PublicationTitleAlternate Drug Metab Pharmacokinet
PublicationYear 2019
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Barnett, Ogungbenro, Menochet, Shen, Lai, Humphreys (bib33) 2018; 104
Yee, Giacomini, Hsueh, Weitz, Liang, Goswami (bib15) 2016; 100
Kiyotani, Mushiroda, Kubo, Zembutsu, Sugiyama, Nakamura (bib36) 2008; 99
Yoshikado, Maeda, Furihata, Terashima, Nakayama, Ishigame (bib29) 2017; 34
Shen, Chen, Drexler, Mandlekar, Holenarsipur, Shields (bib17) 2017; 45
Lee, Ho (bib9) 2017; 83
Chu, Shih, Shaw, Hentze, Chan, Owens (bib11) 2015; 43
Chu, Chan, Evers (bib5) 2017; 106
Shen, Dai, Liu, Cheng, Chen, Freeden (bib12) 2016; 357
Kunze, Ediage, Dillen, Monshouwer, Snoeys (bib24) 2018 Apr 16
Zhang, Yu, He, Fan, Li, Liu (bib27) 2006; 373
Niemi, Pasanen, Neuvonen (bib20) 2011; 63
Njumbe Ediage, Dillen, Vroman, Diels, Kunze, Snoeys (bib31) 2018; 1073
Rodrigues, Taskar, Kusuhara, Sugiyama (bib7) 2018; 103
Lai, Mandlekar, Shen, Holenarsipur, Langish, Rajanna (bib16) 2016; 358
Takehara, Yoshikado, Ishigame, Mori, Furihata, Watanabe (bib18) 2018; 35
Niemi, Pasanen, Neuvonen (bib25) 2006; 80
Bednarczyk, Boiselle (bib19) 2016; 46
Suwannakul, Ieiri, Kimura, Kawabata, Kusuhara, Hirota (bib23) 2008; 53
Gilibili, Chatterjee, Bagul, Mosure, Murali, Mariappan (bib35) 2017; 45
Ieiri, Higuchi, Sugiyama (bib21) 2009; 5
Vaidyanathan, Yoshida, Arya, Zhang (bib4) 2016; 56
Muller, Sharma, Konig, Fromm (bib6) 2018; 70
Kato, Kusuhara, Kumagai, Ieiri, Mori, Ito (bib22) 2012; 22
Yoshida, Guo, Sane (bib34) 2018; 7
Huang, Strong, Zhang, Reynolds, Nallani, Temple (bib1) 2008; 48
Takehara, Terashima, Nakayama, Yoshikado, Yoshida, Furihata (bib14) 2017; 34
Kim, Yoshikado, Ieiri, Maeda, Kimura, Irie (bib30) 2016; 44
Chu, Bleasby, Chan, Nunes, Evers (bib8) 2016; 44
Deng, Song, Shin, Yeo, Cho, Shon (bib26) 2008; 18
DeGorter, Xia, Yang, Kim (bib2) 2012; 52
Maeda (bib10) 2015; 38
Ramanathan, King-Ahmad, Holliman, Rodrigues (bib32) 2017; 9
Konig, Muller, Fromm (bib3) 2013; 65
Thakare, Gao, Kosa, Bi, Varma, Cerny (bib13) 2017; 45
Kashihara, Ieiri, Yoshikado, Maeda, Fukae, Kimura (bib28) 2017; 106
Thakare (10.1016/j.dmpk.2018.09.003_bib13) 2017; 45
Shen (10.1016/j.dmpk.2018.09.003_bib12) 2016; 357
Kim (10.1016/j.dmpk.2018.09.003_bib30) 2016; 44
Shen (10.1016/j.dmpk.2018.09.003_bib17) 2017; 45
Kato (10.1016/j.dmpk.2018.09.003_bib22) 2012; 22
Deng (10.1016/j.dmpk.2018.09.003_bib26) 2008; 18
Kashihara (10.1016/j.dmpk.2018.09.003_bib28) 2017; 106
Niemi (10.1016/j.dmpk.2018.09.003_bib25) 2006; 80
Konig (10.1016/j.dmpk.2018.09.003_bib3) 2013; 65
Ieiri (10.1016/j.dmpk.2018.09.003_bib21) 2009; 5
Muller (10.1016/j.dmpk.2018.09.003_bib6) 2018; 70
Kiyotani (10.1016/j.dmpk.2018.09.003_bib36) 2008; 99
Yoshikado (10.1016/j.dmpk.2018.09.003_bib29) 2017; 34
Chu (10.1016/j.dmpk.2018.09.003_bib5) 2017; 106
Bednarczyk (10.1016/j.dmpk.2018.09.003_bib19) 2016; 46
Takehara (10.1016/j.dmpk.2018.09.003_bib18) 2018; 35
Njumbe Ediage (10.1016/j.dmpk.2018.09.003_bib31) 2018; 1073
Maeda (10.1016/j.dmpk.2018.09.003_bib10) 2015; 38
Ramanathan (10.1016/j.dmpk.2018.09.003_bib32) 2017; 9
Barnett (10.1016/j.dmpk.2018.09.003_bib33) 2018; 104
Lai (10.1016/j.dmpk.2018.09.003_bib16) 2016; 358
Lee (10.1016/j.dmpk.2018.09.003_bib9) 2017; 83
Yee (10.1016/j.dmpk.2018.09.003_bib15) 2016; 100
Yoshida (10.1016/j.dmpk.2018.09.003_bib34) 2018; 7
Huang (10.1016/j.dmpk.2018.09.003_bib1) 2008; 48
Zhang (10.1016/j.dmpk.2018.09.003_bib27) 2006; 373
Suwannakul (10.1016/j.dmpk.2018.09.003_bib23) 2008; 53
Chu (10.1016/j.dmpk.2018.09.003_bib11) 2015; 43
Kunze (10.1016/j.dmpk.2018.09.003_bib24) 2018
Vaidyanathan (10.1016/j.dmpk.2018.09.003_bib4) 2016; 56
DeGorter (10.1016/j.dmpk.2018.09.003_bib2) 2012; 52
Rodrigues (10.1016/j.dmpk.2018.09.003_bib7) 2018; 103
Takehara (10.1016/j.dmpk.2018.09.003_bib14) 2017; 34
Chu (10.1016/j.dmpk.2018.09.003_bib8) 2016; 44
Gilibili (10.1016/j.dmpk.2018.09.003_bib35) 2017; 45
Niemi (10.1016/j.dmpk.2018.09.003_bib20) 2011; 63
References_xml – volume: 45
  start-page: 721
  year: 2017
  end-page: 733
  ident: bib13
  article-title: Leveraging of rifampicin-dosed cynomolgus monkeys to identify bile acid 3-O-sulfate conjugates as potential novel biomarkers for organic anion-transporting polypeptides
  publication-title: Drug Metab Dispos
– volume: 18
  start-page: 424
  year: 2008
  end-page: 433
  ident: bib26
  article-title: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15
  publication-title: Pharmacogenet Genomics
– volume: 44
  start-page: 1498
  year: 2016
  end-page: 1509
  ident: bib8
  article-title: The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist?
  publication-title: Drug Metab Dispos
– volume: 52
  start-page: 249
  year: 2012
  end-page: 273
  ident: bib2
  article-title: Drug transporters in drug efficacy and toxicity
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 56
  start-page: S59
  year: 2016
  end-page: S72
  ident: bib4
  article-title: Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1
  publication-title: J Clin Pharmacol
– volume: 100
  start-page: 524
  year: 2016
  end-page: 536
  ident: bib15
  article-title: Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1
  publication-title: Clin Pharmacol Ther
– volume: 70
  start-page: 246
  year: 2018
  end-page: 277
  ident: bib6
  article-title: Biomarkers for in vivo assessment of transporter function
  publication-title: Pharmacol Rev
– volume: 45
  start-page: 604
  year: 2017
  end-page: 611
  ident: bib35
  article-title: Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay
  publication-title: Drug Metab Dispos
– volume: 99
  start-page: 967
  year: 2008
  end-page: 972
  ident: bib36
  article-title: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
  publication-title: Cancer Sci
– volume: 63
  start-page: 157
  year: 2011
  end-page: 181
  ident: bib20
  article-title: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake
  publication-title: Pharmacol Rev
– volume: 65
  start-page: 944
  year: 2013
  end-page: 966
  ident: bib3
  article-title: Transporters and drug-drug interactions: important determinants of drug disposition and effects
  publication-title: Pharmacol Rev
– volume: 22
  start-page: 344
  year: 2012
  end-page: 354
  ident: bib22
  article-title: Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals
  publication-title: Pharmacogenet Genomics
– volume: 358
  start-page: 397
  year: 2016
  end-page: 404
  ident: bib16
  article-title: Coproporphyrins in plasma and urine can Be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition
  publication-title: J Pharmacol Exp Ther
– volume: 106
  start-page: 2688
  year: 2017
  end-page: 2694
  ident: bib28
  article-title: Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP
  publication-title: J Pharm Sci
– volume: 357
  start-page: 382
  year: 2016
  end-page: 393
  ident: bib12
  article-title: Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species
  publication-title: J Pharmacol Exp Ther
– volume: 48
  start-page: 662
  year: 2008
  end-page: 670
  ident: bib1
  article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
  publication-title: J Clin Pharmacol
– volume: 7
  start-page: 517
  year: 2018
  end-page: 524
  ident: bib34
  article-title: Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics
  publication-title: CPT Pharmacometrics Syst Pharmacol
– volume: 9
  start-page: 1787
  year: 2017
  end-page: 1806
  ident: bib32
  article-title: A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers
  publication-title: Bioanalysis
– volume: 104
  start-page: 564
  year: 2018
  end-page: 574
  ident: bib33
  article-title: Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation
  publication-title: Clin Pharmacol Ther
– year: 2018 Apr 16
  ident: bib24
  article-title: Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions
  publication-title: Clin Pharmacokinet
– volume: 45
  start-page: 908
  year: 2017
  end-page: 919
  ident: bib17
  article-title: Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects
  publication-title: Drug Metab Dispos
– volume: 43
  start-page: 851
  year: 2015
  end-page: 863
  ident: bib11
  article-title: Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans
  publication-title: Drug Metab Dispos
– volume: 44
  start-page: 1622
  year: 2016
  end-page: 1632
  ident: bib30
  article-title: Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information
  publication-title: Drug Metab Dispos
– volume: 106
  start-page: 2357
  year: 2017
  end-page: 2367
  ident: bib5
  article-title: Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions
  publication-title: J Pharmaceut Sci
– volume: 34
  start-page: 1570
  year: 2017
  end-page: 1583
  ident: bib29
  article-title: A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions
  publication-title: Pharm Res
– volume: 373
  start-page: 99
  year: 2006
  end-page: 103
  ident: bib27
  article-title: Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
  publication-title: Clin Chim Acta
– volume: 103
  start-page: 434
  year: 2018
  end-page: 448
  ident: bib7
  article-title: Endogenous probes for drug transporters: balancing vision with reality
  publication-title: Clin Pharmacol Ther
– volume: 5
  start-page: 703
  year: 2009
  end-page: 729
  ident: bib21
  article-title: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
  publication-title: Expert Opin Drug Metab Toxicol
– volume: 1073
  start-page: 80
  year: 2018
  end-page: 89
  ident: bib31
  article-title: Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci
– volume: 38
  start-page: 155
  year: 2015
  end-page: 168
  ident: bib10
  article-title: Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs
  publication-title: Biol Pharm Bull
– volume: 35
  start-page: 138
  year: 2018
  ident: bib18
  article-title: Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers
  publication-title: Pharm Res
– volume: 83
  start-page: 1176
  year: 2017
  end-page: 1184
  ident: bib9
  article-title: Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)
  publication-title: Br J Clin Pharmacol
– volume: 80
  start-page: 356
  year: 2006
  end-page: 366
  ident: bib25
  article-title: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
  publication-title: Clin Pharmacol Ther
– volume: 34
  start-page: 1601
  year: 2017
  end-page: 1614
  ident: bib14
  article-title: Investigation of glycochenodeoxycholate sulfate and chenodeoxycholate glucuronide as surrogate endogenous probes for drug interaction studies of OATP1B1 and OATP1B3 in healthy Japanese volunteers
  publication-title: Pharm Res
– volume: 53
  start-page: 899
  year: 2008
  end-page: 904
  ident: bib23
  article-title: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
  publication-title: J Hum Genet
– volume: 46
  start-page: 457
  year: 2016
  end-page: 466
  ident: bib19
  article-title: Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III
  publication-title: Xenobiotica
– volume: 18
  start-page: 424
  year: 2008
  ident: 10.1016/j.dmpk.2018.09.003_bib26
  article-title: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3282fb02a3
– volume: 103
  start-page: 434
  year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib7
  article-title: Endogenous probes for drug transporters: balancing vision with reality
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.749
– volume: 56
  start-page: S59
  issue: Suppl. 7
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib4
  article-title: Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.723
– volume: 44
  start-page: 1622
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib30
  article-title: Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.116.070276
– volume: 65
  start-page: 944
  year: 2013
  ident: 10.1016/j.dmpk.2018.09.003_bib3
  article-title: Transporters and drug-drug interactions: important determinants of drug disposition and effects
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.113.007518
– volume: 38
  start-page: 155
  year: 2015
  ident: 10.1016/j.dmpk.2018.09.003_bib10
  article-title: Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.b14-00767
– volume: 106
  start-page: 2688
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib28
  article-title: Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2017.03.010
– volume: 80
  start-page: 356
  year: 2006
  ident: 10.1016/j.dmpk.2018.09.003_bib25
  article-title: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.06.010
– volume: 63
  start-page: 157
  year: 2011
  ident: 10.1016/j.dmpk.2018.09.003_bib20
  article-title: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.110.002857
– volume: 1073
  start-page: 80
  year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib31
  article-title: Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci
  doi: 10.1016/j.jchromb.2017.12.008
– volume: 45
  start-page: 908
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib17
  article-title: Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.117.075531
– volume: 52
  start-page: 249
  year: 2012
  ident: 10.1016/j.dmpk.2018.09.003_bib2
  article-title: Drug transporters in drug efficacy and toxicity
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev-pharmtox-010611-134529
– volume: 83
  start-page: 1176
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib9
  article-title: Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.13207
– volume: 22
  start-page: 344
  year: 2012
  ident: 10.1016/j.dmpk.2018.09.003_bib22
  article-title: Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3283517012
– volume: 35
  start-page: 138
  issue: 7
  year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib18
  article-title: Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers
  publication-title: Pharm Res
  doi: 10.1007/s11095-018-2416-3
– volume: 53
  start-page: 899
  year: 2008
  ident: 10.1016/j.dmpk.2018.09.003_bib23
  article-title: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
  publication-title: J Hum Genet
  doi: 10.1007/s10038-008-0324-9
– volume: 46
  start-page: 457
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib19
  article-title: Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2015.1085111
– year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib24
  article-title: Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-018-0648-3
– volume: 9
  start-page: 1787
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib32
  article-title: A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers
  publication-title: Bioanalysis
  doi: 10.4155/bio-2017-0181
– volume: 34
  start-page: 1570
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib29
  article-title: A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions
  publication-title: Pharm Res
  doi: 10.1007/s11095-017-2168-5
– volume: 106
  start-page: 2357
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib5
  article-title: Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions
  publication-title: J Pharmaceut Sci
  doi: 10.1016/j.xphs.2017.04.007
– volume: 5
  start-page: 703
  year: 2009
  ident: 10.1016/j.dmpk.2018.09.003_bib21
  article-title: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425250902976854
– volume: 373
  start-page: 99
  year: 2006
  ident: 10.1016/j.dmpk.2018.09.003_bib27
  article-title: Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2006.05.010
– volume: 357
  start-page: 382
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib12
  article-title: Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.232066
– volume: 358
  start-page: 397
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib16
  article-title: Coproporphyrins in plasma and urine can Be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.234914
– volume: 99
  start-page: 967
  year: 2008
  ident: 10.1016/j.dmpk.2018.09.003_bib36
  article-title: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00765.x
– volume: 70
  start-page: 246
  year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib6
  article-title: Biomarkers for in vivo assessment of transporter function
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.116.013326
– volume: 45
  start-page: 604
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib35
  article-title: Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.116.074740
– volume: 104
  start-page: 564
  year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib33
  article-title: Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.983
– volume: 7
  start-page: 517
  issue: 8
  year: 2018
  ident: 10.1016/j.dmpk.2018.09.003_bib34
  article-title: Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics
  publication-title: CPT Pharmacometrics Syst Pharmacol
  doi: 10.1002/psp4.12315
– volume: 100
  start-page: 524
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib15
  article-title: Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.434
– volume: 43
  start-page: 851
  year: 2015
  ident: 10.1016/j.dmpk.2018.09.003_bib11
  article-title: Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.063347
– volume: 44
  start-page: 1498
  year: 2016
  ident: 10.1016/j.dmpk.2018.09.003_bib8
  article-title: The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist?
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.067694
– volume: 34
  start-page: 1601
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib14
  article-title: Investigation of glycochenodeoxycholate sulfate and chenodeoxycholate glucuronide as surrogate endogenous probes for drug interaction studies of OATP1B1 and OATP1B3 in healthy Japanese volunteers
  publication-title: Pharm Res
  doi: 10.1007/s11095-017-2184-5
– volume: 48
  start-page: 662
  year: 2008
  ident: 10.1016/j.dmpk.2018.09.003_bib1
  article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270007312153
– volume: 45
  start-page: 721
  year: 2017
  ident: 10.1016/j.dmpk.2018.09.003_bib13
  article-title: Leveraging of rifampicin-dosed cynomolgus monkeys to identify bile acid 3-O-sulfate conjugates as potential novel biomarkers for organic anion-transporting polypeptides
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.117.075275
SSID ssj0033542
Score 2.417561
Snippet This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 78
SubjectTerms Adult
Biomarker
Coproporphyrin I
Endogenous substrate
Female
Gender difference
Genotype
Healthy Volunteers
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood
Liver-Specific Organic Anion Transporter 1 - blood
Liver-Specific Organic Anion Transporter 1 - genetics
Male
OATP1B1 genotype
Pharmaceutical Preparations - administration & dosage
Pharmaceutical Preparations - blood
Statin
Substrate Specificity - physiology
Young Adult
Title Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers
URI https://dx.doi.org/10.1016/j.dmpk.2018.09.003
https://www.ncbi.nlm.nih.gov/pubmed/30528195
https://www.proquest.com/docview/2155166876
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBa69LLLsHav7AUNGHpZjciRbMfHrFiRLUAXbCnWm6CXi2yrEtTpIf9hP7qkJCcohvWwkx8QYUGkyc8W-ZGQ97rWnIuaZRU3OhOC8WyU8yJzSlvHK8CwMcv3rJyciy8XxcUeOelqYTCtMvn-6NODt053Bmk1B6vFYvAdiyAFL8G58kBK84DsDyG6sh7ZH3-eTs46h8x5EXro4PgMBVLtTEzzslerX5jhNQp0p13vrL_j07_wZ4hDp4_JowQg6TjO8YDsOX9IjmaRgXpzTOe7gqr2mB7R2Y6bevOE_IlsxXTZ0K_j-Sz_mFNkacUfsS1deroCMH2lqMFiRp8YdVsc7bxdRj7XrWALPidw27ZUeUvt9c0lPBFPw-4DVTvN04WnseJyQ9EfgjYBdj4l56ef5ieTLDVkyAwfsXVWABwQGtY4V4wbp5UQhVCVroTSvFGcWdAGz21lGNONyYV1zIi8MYBZEHjwZ6Tnl969INSqoRN1BfjNGeFGjbKKWfjYK412ZdU0fZJ3apAmsZVj04zfsktL-ylRdRJVJ1mNHKd98mErs4pcHfeOLjrtyjsWJyGY3Cv3rjMFCa8i7q8o72D55TDsOpYQX_rkebSR7TzArYYty5f_-dRX5CFc1TFf_DXpra9v3BuAQ2v9Npk7HqfffkxvAbUlCtk
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfG9gAviPFZYMNIaC8sqjM7SfNYpk0dG6USnbQ3y1-ZCsytlu6h_wN_NHe20woh9sBblPhky3e5-yW--x0hH3StORc1yypudCYE49kg50XmlLaOV4BhY5bvuBxdis9XxdUWOe5qYTCtMvn-6NODt053-mk3-4vZrP8NiyAFL8G58kBK84DsIDsVmPnO8Ox8NO4cMudF6KGD4zMUSLUzMc3L3ix-YIbXINCddr2z_o5P_8KfIQ6dPiGPE4Ckw7jGXbLl_FNyMIkM1KtDOt0UVLWH9IBONtzUq2fkV2QrpvOGfh1OJ_mnnCJLK_6Ibenc0wWA6RtFDRYz-sSo2-Jo5-088rmuBVvwOYHbtqXKW2pv765hRrwMpw9UbTRPZ57GissVRX8I2gTY-Zxcnp5Mj0dZasiQGT5gy6wAOCA0IJhcMW6cVgI2XFW6EkrzRnFmQRs8t5VhTDcmF9YxI_LGAGZB4MFfkG0_9-4VoVYdOVFXgN-cEW7QKKuYhY-90mhXVk3TI3mnBmkSWzk2zfgpu7S07xJVJ1F1ktXIcdojH9cyi8jVce_ootOu_MPiJASTe-Xed6Yg4VXE8xXlHWy_PAqnjiXElx55GW1kvQ5wq-HI8vV_zvqOPBxNv1zIi7Px-RvyCJ7UMXf8Ldle3t65PYBGS72fTP83A5wMJQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+OATP1B1+genotypes+on+plasma+concentrations+of+endogenous+OATP1B1+substrates+and+drugs%2C+and+their+association+in+healthy+volunteers&rft.jtitle=Drug+metabolism+and+pharmacokinetics&rft.au=Mori%2C+Daiki&rft.au=Kashihara%2C+Yushi&rft.au=Yoshikado%2C+Takashi&rft.au=Kimura%2C+Miyuki&rft.date=2019-02-01&rft.issn=1347-4367&rft.volume=34&rft.issue=1&rft.spage=78&rft.epage=86&rft_id=info:doi/10.1016%2Fj.dmpk.2018.09.003&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_dmpk_2018_09_003
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-4367&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-4367&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-4367&client=summon